Genomic Health Inc (GHDX) Files Form 4 Insider Selling : Steven Shak Sells 5,000 Shares

Genomic Health Inc (GHDX): Steven Shak , Chief Scientific Officer of Genomic Health Inc sold 5,000 shares on Jul 19, 2016. The Insider selling transaction was reported by the company on Jul 22, 2016 to the Securities and Exchange Commission. The shares were sold at $27.42 per share for a total value of $137,110.50 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 8, 2016, G Bradley Cole (COO) sold 5,000 shares at $26.65 per share price.On Jun 23, 2016, Steven Shak (Chief Scientific Officer) sold 5,000 shares at $26.21 per share price.Also, On Jun 8, 2016, James J Vaughn (Chief Commercial Officer) sold 1,997 shares at $28.00 per share price.On May 12, 2016, Phillip G. Febbo (Chief Medical Officer) sold 6,324 shares at $27.66 per share price.

Genomic Health: On Wednesday, Jul 20, 2016 heightened volatility was witnessed in Genomic Health which led to swings in the share price. The shares opened for trading at $27.44 and hit $28.01 on the upside , eventually ending the session at $27.92, with a gain of 2.38% or 0.65 points. The heightened volatility saw the trading volume jump to 2,65,662 shares. The 52-week high of the share price is $35.79 and the company has a market cap of $922 M . The 52-week low of the share price is at $20.05.

Genomic Health Money Flow Index Chart

Genomic Health Inc. is a healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company offers its Oncotype DX tests as a clinical laboratory service where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score which it calls a Recurrence Score for invasive breast cancer and colon cancer a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score (GPS) for prostate cancer. The Company’s Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR) in standard tumor pathology specimens to provide tumor-specific information or the oncotype of a tumor. Its offerings also include Oncotype DX Breast Cancer Test Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test.

Leave a Reply

Genomic Health - Is it time to Sell?

Top Brokerage Firms are advising their investors on Genomic Health. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.